Jacobs Levy Equity Management, Inc Travere Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$23.9 Billion
Q3 2025

A detailed history of Jacobs Levy Equity Management, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 318,146 shares of TVTX stock, worth $11 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

318,146

Previous 735,251 56.73%

Holding current value

$11 Million

Previous $10.9 Million 30.13%

% of portfolio

0.03%

Previous 0.04%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 17, 2025	SELL	$14.61 - $27.31 $6.09 Million - $11.4 Million	-417,105 Reduced 56.73%	318,146 $7.6 Million
Q2 2025 Aug 14, 2025	SELL	$13.49 - $21.54 $1.72 Million - $2.75 Million	-127,837 Reduced 14.81%	735,251 $10.9 Million
Q1 2025 May 15, 2025	SELL	$17.07 - $23.75 $22.4 Million - $31.1 Million	-1,311,125 Reduced 60.3%	863,088 $15.5 Million
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $7.97 Million - $11.6 Million	583,836 Added 36.71%	2,174,213 $37.9 Million
Q3 2024 Nov 14, 2024	SELL	$7.89 - $15.21 $2.36 Million - $4.55 Million	-299,467 Reduced 15.85%	1,590,377 $22.2 Million

Q2 2024 Aug 14, 2024	BUY	$5.26 - $8.28 $4.02 Million - $6.34 Million	765,159 Added 68.03%	1,889,844 $15.5 Million
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $4.26 Million - $5.83 Million	-593,513 Reduced 34.54%	1,124,685 $8.67 Million
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $252,568 - $441,066	46,428 Added 2.78%	1,718,198 $15.4 Million
Q3 2023 Nov 16, 2023	BUY	$7.64 - $17.25 $1.12 Million - $2.54 Million	146,970 Added 9.64%	1,671,770 $14.9 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $903,434 - $1.34 Million	59,048 Added 4.03%	1,524,800 $23.4 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $10.4 Million - $13.3 Million	581,490 Added 65.76%	1,465,752 $33 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $2.88 Million - $4.08 Million	156,148 Added 21.45%	884,262 $18.6 Million
Q3 2022 Nov 15, 2022	BUY	$22.91 - $28.63 $3.9 Million - $4.87 Million	170,211 Added 30.51%	728,114 $17.9 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $7.7 Million - $11 Million	-367,541 Reduced 39.72%	557,903 $13.5 Million
Q1 2022 May 16, 2022	SELL	$23.61 - $30.6 $322,229 - $417,628	-13,648 Reduced 1.45%	925,444 $23.8 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $2.27 Million - $2.91 Million	-93,306 Reduced 9.04%	939,092 $29.1 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $3.13 Million - $6.04 Million	241,467 Added 30.53%	1,032,398 $25 Million
Q2 2021 Aug 16, 2021	BUY	$14.11 - $26.4 $2.11 Million - $3.95 Million	149,759 Added 23.36%	790,931 $11.5 Million
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $113,998 - $154,974	-4,878 Reduced 0.76%	641,172 $16 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $12.4 Million - $18 Million	646,050 New	646,050 $17.6 Million

Others Institutions Holding TVTX

# of Institutions

276

Shares Held

101M

Call Options Held

2.36M

Put Options Held

955K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $2.21B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Travere Therapeutics, Inc. Transaction History